Despite its promise, ACT faces several challenges. The complexity of the manufacturing process, the high cost, and the potential for severe side effects such as cytokine release syndrome are significant hurdles. Additionally, the therapy may not be effective for all patients, particularly those with heavily mutated or heterogeneous tumors.
